Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iSpecimen (ISPC) EBIT (2020 - 2025)

iSpecimen has reported EBIT over the past 6 years, most recently at -$2.7 million for Q4 2025.

  • For Q4 2025, EBIT rose 53.98% year-over-year to -$2.7 million; the TTM value through Dec 2025 reached -$9.0 million, up 29.46%, while the annual FY2025 figure was -$9.0 million, 29.46% up from the prior year.
  • EBIT for Q4 2025 was -$2.7 million at iSpecimen, up from -$2.8 million in the prior quarter.
  • Over five years, EBIT peaked at -$942644.0 in Q1 2021 and troughed at -$5.8 million in Q4 2024.
  • A 5-year average of -$2.4 million and a median of -$2.3 million in 2022 define the central range for EBIT.
  • Biggest five-year swings in EBIT: plummeted 401.15% in 2021 and later surged 53.98% in 2025.
  • Year by year, EBIT stood at -$2.0 million in 2021, then fell by 7.35% to -$2.1 million in 2022, then tumbled by 34.06% to -$2.9 million in 2023, then plummeted by 103.43% to -$5.8 million in 2024, then surged by 53.98% to -$2.7 million in 2025.
  • Business Quant data shows EBIT for ISPC at -$2.7 million in Q4 2025, -$2.8 million in Q3 2025, and -$1.8 million in Q2 2025.